Using Plasma HPV-related DNA and RNA to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy
Trial Status: active
This study evaluates the feasibility of circulating human papillomavirus (HPV) deoxyribonucleic acid (DNA)/messenger ribonucleic acid (mRNA), measured by either or both polymerase chain reaction (PCR) or branched DNA (Quantivirus) technology as a liquid biopsy, to evaluate treatment response in cervical cancer. Currently, there is a standard PCR test that detects circulating HPV DNA and mRNA to measure patient response to cervical cancer treatment. The purpose of this study is to see if a new blood test called Quantivirus can also accurately measure response to cervical cancer treatment. The results from the Quantivirus test will be compared to the results from the standard of care test that is currently being used.